Randomised clinical trial: First-line infliximab biosimilar is cost-effective compared to conventional treatment in paediatric Crohn's disease.
Vuijk, Stephanie A. 1; Jongsma, Maria M. E. 1; Hoeven, Britt M. 1; Cozijnsen, Maarten A. 1; van Pieterson, Merel 1; de Meij, Tim G. J. 2; Norbruis, Obbe F. 3; Groeneweg, Michael 4; Wolters, Victorien M. 5; van Wering, Herbert 6; Hummel, Thalia 7; Stapelbroek, Janneke 8; van der Feen, Cathelijne 9; van Rheenen, Patrick F. 10; van Wijk, Michiel P. 2; Teklenburg, Sarah 3; Rizopoulos, Dimitris 11,12; Poley, Marten J. 13,14; Escher, Johanna C. 1; de Ridder, Lissy 1
[Miscellaneous Article] Alimentary Pharmacology & Therapeutics. 59(12):1510-1520, June 2024.

(Format: HTML, PDF)